Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3
- 31 July 2008
- journal article
- clinical trial
- Published by Elsevier BV in Molecular Genetics and Metabolism
- Vol. 94 (3), 319-325
- https://doi.org/10.1016/j.ymgme.2008.03.003
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kgPLOS ONE, 2007
- Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry DiseaseJournal of the American Society of Nephrology, 2007
- Agalsidase-Beta Therapy for Advanced Fabry DiseaseAnnals of Internal Medicine, 2007
- Clinical benefit of enzyme replacement therapy in Fabry diseaseKidney International, 2006
- Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion settingNephrology Dialysis Transplantation, 2005
- Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry DiseaseAmerican Journal of Human Genetics, 2004
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJournal of Medical Genetics, 2001
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseThe New England Journal of Medicine, 2001
- Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene.Journal of Medical Genetics, 1996
- Fabry's Disease: Alpha-Galactosidase DeficiencyScience, 1970